Table 3.
JAK selectivity of systemic JAK inhibitors.
| JAK Inhibitor | IC50 Values (nM) | Indications | |||
|---|---|---|---|---|---|
| JAK1 | JAK2 | JAK3 | TYK2 | ||
| Baricitinib (JAK1/2) | 4.0 | 6.6 | 787 | 61 | AD |
| Upadacitinib (JAK1) | 43 | 120 | 2300 | 4700 | AD, RA, AS |
| Abrocitinib (JAK1) | 29 | 803 | >10.000 | 1259 | AD |
| Tofacitinib (JAK1/2/3) | 15 | 77 | 55 | 489 | RA, AS, PsA, UC, JIA |
AD: atopic dermatitis, AS: ankylosing spondylitis, JAK: janus kinase, JIA: juvenile idiopathic arthritis, PsA: psoriatic arthritis, RA: rheumatoid arthritis, TYK2: tyrosine kinase 2, UC: ulcerative colitis.